A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.